Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has disclosed Other Non-Current Assets for 8 consecutive years, with $614442.4 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Assets rose 556.41% year-over-year to $614442.4, compared with a TTM value of $614442.4 through Dec 2024, up 556.41%, and an annual FY2024 reading of $622344.5, up 561.3% over the prior year.
  • Other Non-Current Assets was $614442.4 for Q4 2024 at Innate Pharma, up from $93606.8 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $614442.4 in Q4 2024 and bottomed at $93606.8 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $240928.1, with a median of $169307.7 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets tumbled 38.42% in 2023, then soared 556.41% in 2024.
  • Year by year, Other Non-Current Assets stood at $175266.6 in 2020, then decreased by 3.4% to $169307.7 in 2021, then decreased by 10.21% to $152016.9 in 2022, then crashed by 38.42% to $93606.8 in 2023, then skyrocketed by 556.41% to $614442.4 in 2024.
  • Business Quant data shows Other Non-Current Assets for IPHA at $614442.4 in Q4 2024, $93606.8 in Q4 2023, and $152016.9 in Q4 2022.